4.8 Article

Neuroprotection by pharmacologic blockade of the GAPDH death cascade

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.0511321103

Keywords

nitric oxide; apoptosis; Parkinson's disease; S-nitrosylation; Siah

Funding

  1. NIDA NIH HHS [DA-00266, DA-00074, P50 DA000266, K05 DA000074] Funding Source: Medline
  2. NIMH NIH HHS [MH-069853, R01 MH069853] Funding Source: Medline
  3. NINDS NIH HHS [P50 NS038377, NS-38377] Funding Source: Medline

Ask authors/readers for more resources

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) participates in a cell death cascade wherein a variety of stimuli activate nitric oxide (NO) synthases with NO nitrosylating GAPDH, conferring on it the ability to bind to Siah, an E3-ubiquitin-ligase, whose nuclear localization signal enables the GAPDH/Siah protein complex to translocate to the nucleus where degradation of Siah targets elicits cell death. R-(-)-Deprenyl (deprenyl) ameliorates the progression of disability in early Parkinson's disease and also has neuroprotective actions. We show that deprenyl and a related agent, TCH346, in subnanomolar concentrations, prevent S-nitrosylation of GAPDH, the binding of GAPDH to Siah, and nuclear translocation of GAPDH. In mice treated with the dopamine neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), low doses of deprenyl prevent binding of GAPDH and Siah1 in the dopamine-enriched corpus striatum.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available